Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy (Q37776777)

23 August 2017

1 reference

title

Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy (English)

1 reference

23 August 2017

Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy (English)

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

14 June 2024

0 references

1 reference

2

Angelika M Vollmar

1 reference

23 August 2017

author name string

Karin von Schwarzenberg

1

1 reference

23 August 2017

Angelika M. Vollmar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20673697

14 June 2024

language of work or name

English

0 references

publication date

31 July 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0304383510003411?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

https://api.elsevier.com/content/article/PII:S0304383510003411?httpAccept=text/plain

14 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

14 June 2024

1 reference

23 August 2017

volume

332

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

295-303

1 reference

Natural products as sources of new drugs over the last 25 years

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

The evolving role of natural products in drug discovery

14 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Panning for chemical gold: marine bacteria as a source of new therapeutics

14 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Marine natural products and related compounds in clinical and advanced preclinical trials

14 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Drug development from marine natural products

14 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

14 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

A New, More Efficient, and Effective Process for the Synthesis of a Key Pentacyclic Intermediate for Production of Ecteinascidin and Phthalascidin Antitumor Agents

14 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B

14 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

14 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

14 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

14 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

14 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.

14 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

14 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Marine pyridoacridine alkaloids and synthetic analogues as antitumor agents

14 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Binding to DNA and cytotoxic evaluation of ascididemin, the major alkaloid from the Mediterranean ascidian Cystodytes dellechiajei

14 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Mechanism of ascididemin-induced cytotoxicity

14 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Ascididemin and meridine stabilise G-quadruplexes and inhibit telomerase in vitro.

14 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells

14 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria

14 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Antineoplastic agents. 398. Isolation and structure elucidation of cephalostatins 18 and 19.

14 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Isolation and structure of cephalostatins 10 and 11

14 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Enantioselective synthesis of (+)-cephalostatin 1

14 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

The cephalostatin way of apoptosis

14 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Role of Smac in cephalostatin-induced cell death

14 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Cephalostatin 1 Inactivates Bcl-2 by Hyperphosphorylation Independent of M-Phase Arrest and DNA Damage

14 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

The Marine Product Cephalostatin 1 Activates an Endoplasmic Reticulum Stress-specific and Apoptosome-independent Apoptotic Signaling Pathway

14 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Cephalostatin 1 selectively triggers the release of Smac/DIABLO and subsequent apoptosis that is characterized by an increased density of the mitochondrial matrix

14 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells

14 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Calpain-1 Regulates Bax and Subsequent Smac-dependent Caspase-3 Activation in Neutrophil Apoptosis

14 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

IAPs, RINGs and ubiquitylation

14 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity

14 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase

14 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9

14 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization

14 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

A novel Apaf-1-independent putative caspase-2 activation complex

14 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress

14 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

RAIDD is required for apoptosis of PC12 cells and sympathetic neurons induced by trophic factor withdrawal

14 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome

14 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Marine natural products: synthetic aspects

14 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP

14 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells

14 June 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis

14 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica

14 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

14 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.

14 June 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

14 June 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

A low-sodium-salt formulation for the fermentation of salinosporamides by Salinispora tropica strain NPS21184.

14 June 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Progress in the discovery of biosynthetic anticancer drugs

14 June 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

14 June 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Bryostatin-1: a novel PKC inhibitor in clinical development

14 June 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1.

14 June 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

14 June 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Apoptosis regulating proteins as targets of therapy for haematological malignancies

14 June 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

14 June 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

14 June 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells

14 June 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification

14 June 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.

14 June 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative

14 June 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

(+)-discodermolide: a marine natural product against cancer.

14 June 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Immunosuppression by discodermolide.

14 June 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

(+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest

14 June 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization

14 June 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells.

14 June 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1)

14 June 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Synthesis and structure determination of kahalalide F (1,2).

14 June 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.

14 June 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

The antitumoral compound Kahalalide F acts on cell lysosomes

14 June 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

Progress in the clinical development of new marine-derived anticancer compounds.

14 June 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.07.004

14 June 2024

Identifiers

1 reference

23 August 2017

1 reference